The latest quarterly report from Fidelity Digital Assets (FDA) Research reveals key insights into the bitcoin and ethereum markets as of Q1 2024. With a detailed analysis of market conditions and future outlooks, FDA’s research report provides several predictions for short and long-term trends.
Fidelity Digital Assets 'Signals' Report Revises Bitcoin Outlook to 'Neutral'
This article was published more than a year ago. Some information may no longer be current.
WRITTEN BY
SHARE
Fidelity Digital Assets Spotlights Bitcoin and Ethereum Market Shifts in New Q1 2024 Report
Fidelity Digital Assets (FDA) Research starts the quarter with a nuanced look at bitcoin’s ( BTC) performance, which saw a notable 64% increase by mid-March, slightly trailing behind ether’s 74%. Despite a slight retraction, the market conditions remain buoyed by the approval of several spot bitcoin exchange-traded products (ETPs).
Alongside this FDA researchers attribute some of the market strength is due to a persistent decrease in BTC’s supply on exchanges. The FDA report further examines selling pressure within the crypto markets, highlighting that currently, this pressure originates from bitcoin miners.
“ Bitcoin began 2024 playing catch-up to ether’s run of 74%, stopping just short at 64% mid-March,” the report explains. “Since then, bitcoin has retraced 2% while ether has fallen roughly 19%. The high fee environment has subsided, but increased spot prices combined with the 2024 halving continue to incentivize miners to take profits. Therefore, miners remain a notable portion of the current sell pressure.”
On ethereum’s ( ETH) front, the report highlights the successful Deneb-Cancun upgrade which has been a boon for ether’s fundamentals, leading to a 55% price increase in Q1. The researchers say that the Ethereum network now boasts a higher burn rate than issuance post-Merge, enhancing its deflationary status. This, coupled with an 8% increase in validator numbers, strengthens the network’s long-term health, according to the FDA study.
The FDA’s findings emphasize the role of technological improvements and regulatory changes in shaping market dynamics. The adoption of layer two (L2) platforms post-Deneb-Cancun upgrade is particularly notable, making up about 80% of ether transactions and contributing to a significant reduction in transaction fees. In addition, the FDA researchers claim that BTC is not cheap and the group has changed its overall outlook from “positive” to “neutral.”
The report states:
Mid-Term (1–5 years) bitcoin is no longer ‘cheap’ and is considered to be trading at ‘fair’ value. Long-term ([greater than] 5 years) overall condition: NEUTRAL.
Looking forward, Fidelity Digital Assets’ analysis indicates a measured optimism. The report observes that although the markets have demonstrated robust growth in Q1, market participants should stay alert to possible selling pressures and corrections. It concludes that the continuous rise in staking is likely to impact market dynamics further, presenting an engaging period for both existing participants and newcomers to the cryptocurrency markets.
What do you think about Fidelity Digital Assets’ analysis? Share your thoughts and opinions about this subject in the comments section below.
